Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Simple organism can produce 10 trillion varieties of a single protein

A team led by University of California, San Diego biochemists has discovered the mechanism by which a simple organism can produce 10 trillion varieties of a single protein, a finding that provides a new tool to develop novel drugs.

21 Sep 2005

Vaccine against group B streptococcus

Common bacteria that live harmlessly in the gastrointestinal tract and vagina of 25 percent of women can become lethal if a newborn gets exposed to them during birth.

20 Sep 2005

Researchers identify three rapid diagnostic methods that can target antibodies commonly found in multiple sclerosis

Yale School of Medicine researchers have identified three rapid diagnostic methods that can target antibodies commonly found in multiple sclerosis (MS) patients, greatly improving potential diagnosis and treatment.

20 Sep 2005

O-GlcNAc sugar is a critical regulator of cells' natural life cycle

The discovery reveals that, when disturbed, this process could contribute to cancer or other diseases by failing to properly control the steps and timing of cell division, the researchers say. The findings are described in the Sept. 23 issue of the Journal of Biological Chemistry, available online now.

20 Sep 2005

SARS can infiltrate brain tissue

Severe acute respiratory syndrome (SARS), by its very name, indicates a disease of the respiratory tract. But SARS can also infiltrate brain tissue, causing significant central nervous system problems, according to an article in the Oct. 15 issue of Clinical Infectious Diseases, now available online.

20 Sep 2005

Study suggests chronic infections may create autoimmune response

New research finds the human immune system has foregone evolutionary changes that would allow it to produce better antibodies in less time because the improved antibodies would be far more likely to attack the body's own tissues.

19 Sep 2005

Retinoic acid combined with PIC, a synthetic immunity booster, significantly elevates the immune system response to a tetanus shot

These results show that a natural product of vitamin A can have an important role in regulating immunity and, when administered along with PIC, might be a potentially powerful nutritional-immunological assist in vaccination."

12 Sep 2005

Workshop - stem cells in reproduction and in the brain

"Once we have found the factors by which body cells can be re-programmed into stem cells, then therapeutic cloning might become superfluous," said Hans R. Scholer, director of the Max Planck Institute for Molecular Biomedicine in Munster, Germany, at an international scientific symposium on stem cell research in Kobe, Japan.

10 Sep 2005

Collaborators seek parasite invasion blockers

A malaria research team, including WEHI Structural Biologist, Professor Ray Norton, has received a US$1 million grant from the US National Institutes of Health to develop more effective malaria treatments.

7 Sep 2005

New way to assess risk of breast cancer recurrence

Currently, the best way to predict whether a breast cancer is likely to recur is to determine whether tumor cells have invaded the lymph nodes near the breast.

5 Sep 2005

New vaccine with the potential to protect against fungal pathogens

A group of scientists in Italy have developed a vaccine with the potential to protect against fungal pathogens that commonly infect humans, according to a study by Torosantucci and colleagues in the September 5 issue of The Journal of Experimental Medicine.

5 Sep 2005

Domantis successful in patent opposition

Domantis Limited, the human Domain Antibody Therapeutics company, has successfully opposed European patent number EP0656946, leading to a major amendment of the main claim in the patent and a significant narrowing of the scope of 34 of the 41 other claims.

1 Sep 2005

Emergent Biosolutions' typhoid vaccine achieves positive results in Phase II clinical study

Emergent BioSolutions today announced positive results from a Phase II clinical study evaluating a new simplified dosing regimen for the company's next generation single dose oral typhoid vaccine. The results of the study were published in the August edition of the Journal of Infectious Diseases.

30 Aug 2005

New treatment can zap cancer cells and avoid healthy tissue

Australian researchers say they have developed a cancer treatment which can identify and kill individual cancer cells.

30 Aug 2005

Anti-cancer antibodies produced in chickens

A team of researchers have produced the first fully functional, human sequence monoclonal antibodies (mAbs) in chickens.

29 Aug 2005

Three-dimensional molecular structure of a promising malaria-vaccine component

An international team of scientists that includes a researcher from the U.S. Department of Energy's Brookhaven National Laboratory has determined the three-dimensional molecular structure of a promising malaria-vaccine component.

29 Aug 2005

New laboratory method for quickly detecting active anthrax proteins

A new laboratory method for quickly detecting active anthrax proteins within an infected blood sample at extremely low levels has been developed by researchers at the National Institute of Standards and Technology (NIST), the U.S. Army Medical Research Institute of Infectious Diseases and the National Cancer Institute.

29 Aug 2005

Carbohydrate-based vaccine against cancer?

Couldn't we be immunized against cancer? This sounds like a dream, but is in fact a thoroughly realistic research goal. American researchers have now taken an important step forward in the development of a cancer vaccine.

29 Aug 2005

New strategy to turn off the function of a special group of T cells to suppress immune response to tumors

A special stretch of genetic material may turn off the immune suppression that stymies attempts to fight cancer with a vaccine, said researchers at Baylor College of Medicine (BCM) at Houston.

26 Aug 2005

First clinical trial of a biologic nanoparticle designed to give back to cancer patients the tumor-busting gene they have lost

The phase I clinical study will enroll 20 patients with advanced solid cancers (including most common tumor types), and is the culmination of more than a decade of work by a team of researchers led by Professor Esther H. Chang, Ph.D. at the Lombardi Comprehensive Cancer Center.

25 Aug 2005